• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PPARs 对胆汁酸和胆固醇代谢的调节。

Regulation of bile acid and cholesterol metabolism by PPARs.

机构信息

Department of Integrative Medical Sciences, Northeastern Ohio Universities College of Medicine, Rootstown, OH 44272, USA.

出版信息

PPAR Res. 2009;2009:501739. doi: 10.1155/2009/501739. Epub 2009 Jul 14.

DOI:10.1155/2009/501739
PMID:19636418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2712638/
Abstract

Bile acids are amphipathic molecules synthesized from cholesterol in the liver. Bile acid synthesis is a major pathway for hepatic cholesterol catabolism. Bile acid synthesis generates bile flow which is important for biliary secretion of free cholesterol, endogenous metabolites, and xenobiotics. Bile acids are biological detergents that facilitate intestinal absorption of lipids and fat-soluble vitamins. Recent studies suggest that bile acids are important metabolic regulators of lipid, glucose, and energy homeostasis. Agonists of peroxisome proliferator-activated receptors (PPARα, PPARγ, PPARδ) regulate lipoprotein metabolism, fatty acid oxidation, glucose homeostasis and inflammation, and therefore are used as anti-diabetic drugs for treatment of dyslipidemia and insulin insistence. Recent studies have shown that activation of PPARα alters bile acid synthesis, conjugation, and transport, and also cholesterol synthesis, absorption and reverse cholesterol transport. This review will focus on the roles of PPARs in the regulation of pathways in bile acid and cholesterol homeostasis, and the therapeutic implications of using PPAR agonists for the treatment of metabolic syndrome.

摘要

胆汁酸是在肝脏中从胆固醇合成的两亲分子。胆汁酸合成是肝脏胆固醇分解代谢的主要途径。胆汁酸合成产生胆汁流,这对于胆汁中游离胆固醇、内源性代谢物和外源性化合物的分泌很重要。胆汁酸是促进脂质和脂溶性维生素吸收的生物清洁剂。最近的研究表明,胆汁酸是脂质、葡萄糖和能量稳态的重要代谢调节剂。过氧化物酶体增殖物激活受体 (PPARα、PPARγ、PPARδ) 的激动剂调节脂蛋白代谢、脂肪酸氧化、葡萄糖稳态和炎症,因此被用作治疗血脂异常和胰岛素抵抗的抗糖尿病药物。最近的研究表明,PPARα 的激活改变了胆汁酸的合成、结合和转运,以及胆固醇的合成、吸收和逆向胆固醇转运。这篇综述将重点介绍 PPAR 在调节胆汁酸和胆固醇稳态途径中的作用,以及使用 PPAR 激动剂治疗代谢综合征的治疗意义。

相似文献

1
Regulation of bile acid and cholesterol metabolism by PPARs.PPARs 对胆汁酸和胆固醇代谢的调节。
PPAR Res. 2009;2009:501739. doi: 10.1155/2009/501739. Epub 2009 Jul 14.
2
Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.治疗胰岛素抵抗、2型糖尿病和代谢综合征的新方法:同时激活过氧化物酶体增殖物激活受体α、γ和δ
Curr Diabetes Rev. 2005 Aug;1(3):299-307. doi: 10.2174/157339905774574365.
3
The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.过氧化物酶体增殖物激活受体β/δ激动剂GW501516可调节骨骼肌细胞中参与脂质分解和能量解偶联的基因表达。
Mol Endocrinol. 2003 Dec;17(12):2477-93. doi: 10.1210/me.2003-0151. Epub 2003 Oct 2.
4
Bile acid signaling in metabolic disease and drug therapy.代谢性疾病与药物治疗中的胆汁酸信号传导
Pharmacol Rev. 2014 Oct;66(4):948-83. doi: 10.1124/pr.113.008201.
5
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.过氧化物酶体增殖物激活受体在脂质代谢和动脉粥样硬化中的多效性作用
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):717-26. doi: 10.1161/01.atv.0000015598.86369.04.
6
The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism.过氧化物酶体增殖物激活受体在胆汁酸代谢调节中的作用。
Basic Clin Pharmacol Toxicol. 2024 Mar;134(3):315-324. doi: 10.1111/bcpt.13971. Epub 2023 Dec 15.
7
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer.胆汁酸在胆汁淤积、炎症和癌症中的代谢与信号传导
Adv Pharmacol. 2015;74:263-302. doi: 10.1016/bs.apha.2015.04.003. Epub 2015 May 27.
8
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.胆汁酸信号在代谢和炎症性疾病及药物研发中的作用
Pharmacol Rev. 2024 Oct 16;76(6):1221-1253. doi: 10.1124/pharmrev.124.000978.
9
Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges.胆汁酸对肝脏生理的调节:III. 胆汁酸合成的调节:过去的进展与未来的挑战。
Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G551-7. doi: 10.1152/ajpgi.00468.2002.
10
The Role of PPARs in Cancer.过氧化物酶体增殖物激活受体(PPARs)在癌症中的作用。
PPAR Res. 2008;2008:102737. doi: 10.1155/2008/102737.

引用本文的文献

1
Bile Acid Metabolism Changes in Patients with a -Associated Inherited Retinal Degeneration.α-相关遗传性视网膜变性患者的胆汁酸代谢变化
Ophthalmol Sci. 2025 Jan 7;5(4):100704. doi: 10.1016/j.xops.2025.100704. eCollection 2025 Jul-Aug.
2
Pediatric Familial Hypercholesterolemia: Targeting Intestinal Absorption and Other Therapeutic Strategies.小儿家族性高胆固醇血症:针对肠道吸收及其他治疗策略
Nutrients. 2025 Jul 18;17(14):2357. doi: 10.3390/nu17142357.
3
Millets: Journey from an Ancient Crop to Sustainable and Healthy Food.小米:从古老作物到可持续健康食品的历程。

本文引用的文献

1
Lipid-activated transcription factors control bile acid glucuronidation.脂质激活转录因子控制胆汁酸葡萄糖醛酸化。
Mol Cell Biochem. 2009 Jun;326(1-2):3-8. doi: 10.1007/s11010-008-0001-5. Epub 2009 Jan 7.
2
Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers.过氧化物酶体增殖物激活受体α在全氟辛酸和全氟癸酸诱导的小鼠肝脏中有机阴离子转运多肽摄取转运体下调中的关键作用。
Toxicol Sci. 2008 Nov;106(1):37-45. doi: 10.1093/toxsci/kfn161. Epub 2008 Aug 14.
3
Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.
Foods. 2025 May 13;14(10):1733. doi: 10.3390/foods14101733.
4
Gut-Microbiota-Driven Lipid Metabolism: Mechanisms and Applications in Swine Production.肠道微生物群驱动的脂质代谢:机制及其在养猪生产中的应用
Metabolites. 2025 Apr 4;15(4):248. doi: 10.3390/metabo15040248.
5
Single and Multiple Doses of Seladelpar Decrease Diurnal Markers of Bile Acid Synthesis in Mice.单剂量和多剂量的塞拉地帕降低小鼠胆汁酸合成的昼夜标志物
PPAR Res. 2025 Mar 11;2025:5423221. doi: 10.1155/ppar/5423221. eCollection 2025.
6
Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma.肠道嗜黏蛋白阿克曼氏菌可增强PD1疗法对MAFLD相关肝细胞癌的疗效。
Cell Rep Med. 2025 Jan 21;6(1):101900. doi: 10.1016/j.xcrm.2024.101900. Epub 2025 Jan 10.
7
Immune Implications of Cholesterol-Containing Lipid Nanoparticles.载脂蛋白胆固醇脂质纳米颗粒的免疫相关性。
ACS Nano. 2024 Oct 22;18(42):28480-28501. doi: 10.1021/acsnano.4c06369. Epub 2024 Oct 10.
8
Sensitive Profiling of Mouse Liver Membrane Proteome Dysregulation Following a High-Fat and Alcohol Diet Treatment.高脂和酒精饮食处理后小鼠肝膜蛋白质组失调的灵敏分析
Proteomics. 2024 Dec;24(23-24):e202300599. doi: 10.1002/pmic.202300599. Epub 2024 Sep 23.
9
Anti-tumor effect and hepatotoxicity mechanisms of psoralen.补骨脂素的抗肿瘤作用及肝毒性机制
Front Pharmacol. 2024 Aug 5;15:1442700. doi: 10.3389/fphar.2024.1442700. eCollection 2024.
10
A Mixture of HY7601 and KY1032 Regulates Energy Metabolism in Adipose Tissue and Improves Cholesterol Disposal in High-Fat-Diet-Fed Mice.HY7601 和 KY1032 的混合物调节脂肪组织中的能量代谢,并改善高脂肪饮食喂养的小鼠中的胆固醇处置。
Nutrients. 2024 Aug 5;16(15):2570. doi: 10.3390/nu16152570.
过氧化物酶体增殖物激活受体δ诱导肥胖糖尿病小鼠的胰岛素诱导基因-1并抑制肝脏脂肪生成。
Hepatology. 2008 Aug;48(2):432-41. doi: 10.1002/hep.22334.
4
Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.肝脏X受体对PPARα基因转录的肠道特异性调控
Endocrinology. 2008 Oct;149(10):5128-35. doi: 10.1210/en.2008-0637. Epub 2008 Jun 19.
5
Recent advances in liver X receptor biology and chemistry.肝脏X受体生物学与化学的最新进展。
Curr Top Med Chem. 2008;8(9):781-91. doi: 10.2174/156802608784535075.
6
Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver.Ostalpha - Ostbeta对于肠道、肾脏和肝脏中胆汁酸及共轭类固醇的代谢是必需的。
Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G179-G186. doi: 10.1152/ajpgi.90319.2008. Epub 2008 May 22.
7
PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine.在小肠中,过氧化物酶体增殖物激活受体α(PPARα)基因表达受肝脏X受体(LXR)和孕烷X受体(PXR)激活剂上调。
Biochem Biophys Res Commun. 2008 Jul 11;371(4):675-8. doi: 10.1016/j.bbrc.2008.04.100. Epub 2008 Apr 28.
8
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.过氧化物酶体增殖物激活受体在非酒精性脂肪性肝病发病机制及治疗中的作用
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
9
Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets.非酒精性脂肪性肝病:发病机制及核受体作为治疗靶点的潜力
Mol Pharm. 2008 Jan-Feb;5(1):49-59. doi: 10.1021/mp700110z. Epub 2007 Dec 12.
10
Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.过氧化物酶体增殖物激活受体α激动剂治疗改善梗阻性黄疸大鼠肝损伤:一项实验研究。
BMC Gastroenterol. 2007 Nov 28;7:44. doi: 10.1186/1471-230X-7-44.